Carl Zeiss Meditec : Weak start to 2024 already well reflected
>Q4 preview – Focus on 2024 guidance - Q4 revenues of € 605m (+6.2% y-o-y) should be supported by 10% growth in Microsurgery, while we expect only 5% growth for Ophthalmic devices. On the bottom line, we forecast an adj. EBIT of € 112.9m (margin 18.7%, -6.4% y-o-y), impacted by consumable destocking in China. Our Q4 EPS estimate stands at € 0.52. However, we regard the guidance for 2024 as key as a weak start has been already communicated and the focus of investors wi...Carl Zeiss Meditec is a holding company. Co.'s businesses are focused on two primary areas: Ophthalmology and Microsurgery. In Ophthalmology, Co.'s operations are divided in to two strategic business units: Ophthalmic Systems, which includes a range of laser and diagnostic systems for ophthalmology; and Surgical Ophthalmology, which consists of activities in the field of ophthalmic implants and consumables. In Microsurgery, Co. provides surgical microscopes and visualization solutions, e. g. for ear, nose and throat surgery, or neurosurgery. These products are mainly used to assist with the removal of tumors, as well as the treatment of vascular diseases and functional disorders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.